Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00425360
Status:
COMPLETED
Last Update Posted:
2013-08-26
First Post:
2007-01-19
Brief Title:
Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sponsor:
Royal Liverpool University Hospital
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Prospective Phase III Controlled Multicentre Randomised Clinical Trial Comparing Combination Gemcitabine and Capecitabine Therapy With Concurrent and Sequential Chemoimmunotherapy Using a Telomerase Vaccine in Locally Advanced and Metastatic Pancreatic Cancer TELOVAC
Status:
COMPLETED
Status Verified Date:
2009-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy such as gemcitabine and capecitabine work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing Vaccines made from peptides may help the body build an effective immune response to kill tumor cells Giving more than one drug combination chemotherapy together with vaccine therapy may kill more tumor cells It is not yet known whether chemotherapy is more effective with or without vaccine therapy in treating pancreatic cancer
PURPOSE This randomized phase III trial is studying gemcitabine capecitabine and vaccine therapy to see how well they work compared with gemcitabine and capecitabine alone in treating patients with locally advanced or metastatic pancreatic cancer
PURPOSE This randomized phase III trial is studying gemcitabine capecitabine and vaccine therapy to see how well they work compared with gemcitabine and capecitabine alone in treating patients with locally advanced or metastatic pancreatic cancer
Detailed Description:
OBJECTIVES
Primary
Determine the efficacy of telomerase peptide vaccine GV1001 when administered concurrently or sequentially with gemcitabine hydrochloride and capecitabine in terms of survival in patients with locally advanced or metastatic pancreatic cancer
Secondary
Determine the safety of this regimen in these patients
Assess the immunogenicity of this regimen in these patients
Determine the time to progression in patients treated with this regimen
Determine the quality of life of patients treated with this regimen
Determine the clinical benefit response in patients treated with this regimen
Determine the objective response rate in patients treated with this regimen
Determine the toxicity of this regimen in these patients
Determine the survival and response by delayed-type hypersensitivity in patients treated with this regimen
OUTLINE This is a prospective controlled randomized open-label multicenter study Patients are stratified according to stage of disease locally advanced vs metastatic and ECOG performance status 0 vs 1 vs 2 Patients are randomized to 1 of 3 treatment arms
Arm I Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 8 and 15 and oral capecitabine twice daily on days 1-21 Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity
Arm II Patients receive gemcitabine hydrochloride and capecitabine as in arm I Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity Patients then receive sargramostim GM-CSF intradermally ID and telomerase peptide vaccine GV1001 ID on days 1 3 and 5 in week 9 once a week in weeks 10-12 and 14 and then once a month in the absence of disease progression or unacceptable toxicity Patients who develop disease progression while on vaccine therapy discontinue vaccine therapy and then restart treatment with gemcitabine hydrochloride and capecitabine Patients receive gemcitabine hydrochloride and capecitabine as above and continue treatment in the absence of further disease progression or unacceptable toxicity
Arm III Patients receive gemcitabine hydrochloride and capecitabine as in arm I Patients also receive GM-CSF ID and telomerase peptide vaccine GV1001 ID on days 1 3 and 5 in week 1 once weekly in weeks 2 3 4 and 6 and then once a month in the absence of disease progression or unacceptable toxicity
Quality of life is assessed at baseline and at 8 weeks and then every 12 weeks during study treatment
After completion of study treatment patients are followed every 3 months
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL A total of 1110 patients will be accrued for this study
Primary
Determine the efficacy of telomerase peptide vaccine GV1001 when administered concurrently or sequentially with gemcitabine hydrochloride and capecitabine in terms of survival in patients with locally advanced or metastatic pancreatic cancer
Secondary
Determine the safety of this regimen in these patients
Assess the immunogenicity of this regimen in these patients
Determine the time to progression in patients treated with this regimen
Determine the quality of life of patients treated with this regimen
Determine the clinical benefit response in patients treated with this regimen
Determine the objective response rate in patients treated with this regimen
Determine the toxicity of this regimen in these patients
Determine the survival and response by delayed-type hypersensitivity in patients treated with this regimen
OUTLINE This is a prospective controlled randomized open-label multicenter study Patients are stratified according to stage of disease locally advanced vs metastatic and ECOG performance status 0 vs 1 vs 2 Patients are randomized to 1 of 3 treatment arms
Arm I Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 8 and 15 and oral capecitabine twice daily on days 1-21 Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity
Arm II Patients receive gemcitabine hydrochloride and capecitabine as in arm I Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity Patients then receive sargramostim GM-CSF intradermally ID and telomerase peptide vaccine GV1001 ID on days 1 3 and 5 in week 9 once a week in weeks 10-12 and 14 and then once a month in the absence of disease progression or unacceptable toxicity Patients who develop disease progression while on vaccine therapy discontinue vaccine therapy and then restart treatment with gemcitabine hydrochloride and capecitabine Patients receive gemcitabine hydrochloride and capecitabine as above and continue treatment in the absence of further disease progression or unacceptable toxicity
Arm III Patients receive gemcitabine hydrochloride and capecitabine as in arm I Patients also receive GM-CSF ID and telomerase peptide vaccine GV1001 ID on days 1 3 and 5 in week 1 once weekly in weeks 2 3 4 and 6 and then once a month in the absence of disease progression or unacceptable toxicity
Quality of life is assessed at baseline and at 8 weeks and then every 12 weeks during study treatment
After completion of study treatment patients are followed every 3 months
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL A total of 1110 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ISRTCN43482138 | None | None | None |
| CRUK-TELOVAC-V4 | None | None | None |
| EUDRACT-2006-000461-10 | None | None | None |
| EU-20683 | None | None | None |